Saxagliptin hydrateSaxagliptin hydrate
MedChemExpress (MCE)
HY-10285A
945667-22-1
BMS-477118 hydrate
98.13%
-20°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light, stored under nitrogen)
Room temperature in continental US
may vary elsewhere.
Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research.
Saxagliptin (100 nM
48 hours
INS-1 832/13 cells) treatment significantly induceS β-cell proliferation[1]. Saxagliptin (100 nM
48 hours
INS-1 832/13 cells) treatment increases the p-AKT and active β-catenin protein levels, paralleled with the increase of c-myc and cyclin D1 protein expression[1]. Saxagliptin acts by preventing the degradation of glucagon-like peptide-1 and hence increases secretion of insulin and decreases secretion of glucagon[3].
Saxagliptin (1 mg/kg
for 12 weeks) treatment in high-fat diet/streptozotocin-induced diabetic rats, significant improvement in pancreas insulin secretion capacity evaluated by hyperglycemia clamp and increased β-cell to α-cell areas ratio are observed[1]. Saxagliptin dose-dependently inhibits plasma DPP-4 activity in Han-Wistar rats, by ~70% at 7 hours postdose with 1 mg/kg and by ~90% at 7 hours postdose with 10 mg/kg. At 24 hours postdose, ~20% and 70% inhibition, respectively, remained[2].
DPP-4
| | | |
| | | | | |
[1]. Chun-Jun Li, et al. Saxagliptin Induces β-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1α In Vivo and In Vitro. Front Endocrinol (Lausanne). 2017 Nov 27
8:326. [Content Brief]
[2]. Darshan J Dave. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother. 2011 Oct
2(4):230-5. [Content Brief]
[3]. Carolyn F Deacon, et al. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther. 2009 May
26(5):488-99. [Content Brief]